Purchase Details

Company: Exact Sciences
Ticker:EXAS
Yahoo Beta:1.46
Industry:Diagnostics & research

Company Description:  Exact Sciences is a genomics company that provides screening tests for certain cancers and also provides information for targeted therapies based on the specific cancer type.

Purchase Date:18 Mar 2021
Purchase Price:$127.30
  --Split Adjusted:$127.30
Shares Purchased:20
  --Split Adjusted:20
Transaction Fee:$0.00
Price Range (6 Months Prior):    
High$155.01
Date12 Feb 2021
Low$72.92
Date22 Sep 2020
S&P (Purchase Date):$3,923.73

Timing:  We bought a bit above the midpoint of the six-month trading range.
Reason:  Exact Sciences has two key products, Cologard and Oncotype IQ. Cologard is a non-invasive test for colon cancer and Oncotype sequences genes in cancer cells to help select the best treatment options. The companies tests combine information from cells' genomes with information about the proteins expressed by cancer cells. The company has a dominant market position, resulting in a large and increasingly large proprietary data set. The company has formed attractive partnerships with Pfizer and Epic.

Total Spent:   $2,546.00